CAPR Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CAPR Investors with Losses to Contact the Firm
CAPR Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CAPR Investors with Losses to Contact the Firm CAPR Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CAPR Investors with Losses to Contact the Firm PR Newswire RADNOR, Pa., Aug. 16, 2026 Did you buy CAPR securities...
PR Newswire
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact...
PR Newswire
Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman
Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman PR Newswire SAN FRANCISCO, Aug. 14, 2026...
PR Newswire
Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action Lawsuit Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Capricor Therapeutics, Inc. (Capricor) (NASDAQ: CAPR) on behalf of those who purchased or acquired...
Business Wire
The Money Machine Is Back, as Biotech, AI, and Tech Names Explode
Today’s stock market coverage illustrates two very different kinds of momentum. NeOnc (NASDAQ:NTHI), MDxHealth (NASDAQ:MDXH), and Capricor Therapeutics (NASDAQ:CAPR) are fundamentally driven healthcare stories, where clinical data, regulatory decisions, diagnostics adoption and cash runway determine whether today's enthusiasm can become a durable rerating, while Wetour Robotics (NASDAQ:WETO), Onfolio Holdings (NASDAQ:ONFO), and Creative Global Technology Holdings (NASDAQ: CGTL) are much more structure-sensitive.
24-7 Market News
Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval
Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash position of $approximately $237.9 million.read more...
Benzinga
CAPR’s FDA Showdown Is Here: The Advisory Committee Said No, But the Real Decision Hasn’t Happened Yet
The market may be treating Capricor Therapeutics (NASDAQ:CAPR) as if the July 29 FDA advisory committee vote delivered a knockout blow, but it didn't. It delivered a major setback, but the actual regulatory story appears to be considerably more complicated and, with the Deramiocel BLA still under active FDA review and a PDUFA action date of August 22, the most important decision has yet to be made.
24-7 Market News